Innate Immune Response of Blood Cells in Patients With Pneumonia

Lobar Pneumonia Clinical Trial

— ASTRAL  

Official title:

Analysis of Blood Cells Innate Immune Response in Patients With Lobar Pneumonia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03231670
• Other study ID #: RT-12
• Status: Completed
• Start date: October 20, 2017
• Est. completion date: June 24, 2020

Study information

• Verified date: March 2024
• Source: Lille Catholic University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Pulmonary bacterial infections such as exacerbations of chronic bronchitis, nosocomial and community-acquired pneumonia represent a major public health issue. Antibiotics have shown their efficacy by direct antimicrobial activity and their limit particularly in case of multidrug-resistant microorganisms or in treating patients with aggravating pathologies. Innate immunity could be an alternative or complementary therapeutic pathway. Innate immunity receptors bind universal and invariant microbial molecular patterns present in bacteria, virus, fungus or parasite. Toll-like Receptors (TLR) activation by microbial agonist stimulates the innate immunity response which results in the production of chemokines, cytokines, antimicrobial molecules and the recruitment of innate cells.

The " Pulmonary Infection and Innate Immunity " team of the Immunity and Infection Center in Lille (Group of Dr. Sirard and Carnoy) has a long expertise in the study of TLR5 and its agonist, the flagellin, a structural protein of bacterial flagella. TLR5 is expressed on the cell surface of macrophages, monocytes, dendritic and epithelial cells. Several studies in mice have shown the flagellin prophylactic potential during bacterial infections through a TLR5 dependent stimulation of innate immunity. Recently, the group of Dr. Sirard and Carnoy has shown that flagellin can be used in association with antibiotics to treat Streptococcus pneumoniae respiratory infections in mice. The results demonstrate that an agonist of TLR can increase the therapeutic index of an antibiotic and improve the pulmonary anti-infectious reaction. This innovative approach allows us to consider new antibacterial strategies where antibiotics have reached their limit (nosocomial infection, multidrug-resistant bacteria…). TLR agonists can activate multiple human cell type. Indeed, blood cells activation by TLR agonists have been recently characterized in healthy volunteers.

However, there is no available data on the ability of TLR agonists to activate cells from patients with infectious pneumopathies. A study in these patients is inevitable if one is to consider the therapeutic use of agonists in respiratory pathologies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: June 24, 2020
• Est. primary completion date: June 24, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patient hospitalized in the department of pneumology for whom clinical, radiological and biological criteria confirm the diagnosis of lobar pneumonia

• Beneficiary of the French National Health Insurance Fund

• Signed informed consent form

Exclusion Criteria:

• Patient under guardianship

• Patient with acute respiratory distress syndrome or septic shock

• Pregnant women

• Patient with HIV, HCV or Mycobacterium tuberculosis

• Transplanted patient receiving immunosuppressive therapy

Related Conditions & MeSH terms

• Lobar Pneumonia
• Pneumonia

Intervention

Procedure:
• Blood sampling
5ml blood will be taken in addition to standard sampling

Locations

Country	Name	City	State
France	Hôpital Saint-Philibert	Lomme	Hauts De France

Sponsors (2)

Lead Sponsor	Collaborator
Lille Catholic University	Institut Pasteur de Lille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in IL-6 specific transcripts	IL-6 specific transcripts will be measured in blood mononuclear cells after stimulation with a TLR5 agonist.	Baseline and 2 months
Secondary	Change in expression of innate immunity genes after stimulation by TLR2 agonist		Baseline and 2 months
Secondary	Change in expression of innate immunity genes after stimulation by TLR4 agonist		Baseline and 2 months
Secondary	Change in expression of innate immunity genes after stimulation by TLR5 agonist		Baseline and 2 months
Secondary	Change in expression of innate immunity genes after stimulation by TLR9 agonist		Baseline and 2 months
Secondary	Change in ELISA assay on mediators of inflammation with stimulation by TRL2 agonist	ELISA assay on mediators of inflammation in the supernatant of blood mononuclear cells stimulated by TRL2 agonist	Baseline and 2 months
Secondary	Change in ELISA assay on mediators of inflammation with stimulation by TRL4 agonist	ELISA assay on mediators of inflammation in the supernatant of blood mononuclear cells stimulated by TRL4 agonist	Baseline and 2 months
Secondary	Change in ELISA assay on mediators of inflammation with stimulation by TRL5 agonist	ELISA assay on mediators of inflammation in the supernatant of blood mononuclear cells stimulated by TRL5 agonist	Baseline and 2 months
Secondary	Change in ELISA assay on mediators of inflammation with stimulation by TRL9 agonist	ELISA assay on mediators of inflammation in the supernatant of blood mononuclear cells stimulated by TRL9 agonist	Baseline and 2 months
Secondary	Genotyping of TLR 2 gene		Baseline
Secondary	Genotyping of TLR 4 gene		Baseline
Secondary	Genotyping of TLR 5 gene		Baseline
Secondary	Genotyping of TLR 9 gene		Baseline